AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
India · Delayed Price · Currency is INR 8,433.50
-95.50 (-1.12%)
Jun 19, 2026, 3:29 PM IST
AstraZeneca Pharma India Revenue
In the fiscal year ending March 31, 2026, AstraZeneca Pharma India had annual revenue of 22.76B INR with 32.59% growth. AstraZeneca Pharma India had revenue of 5.79B in the quarter ending March 31, 2026, with 20.42% growth.
Revenue
22.76B
Revenue Growth
+32.59%
P/S Ratio
9.24
Revenue / Employee
37.93M
Employees
600
Market Cap
210.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.76B | 5.59B | 32.59% |
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 96.46B |
| Emcure Pharmaceuticals | 92.04B |
| Piramal Pharma | 88.69B |
| Alembic Pharmaceuticals | 73.45B |
| Gland Pharma | 64.31B |
| Ajanta Pharma | 54.53B |
| NATCO Pharma | 40.78B |
| Wockhardt | 33.73B |
AstraZeneca Pharma India News
- 3 days ago - AstraZeneca Pharma India appoints Praveen K Mittal as Director - Corporate Affairs - Business Upturn
- 7 days ago - AstraZeneca Pharma India announces resignation of senior management personnel - Business Upturn
- 8 days ago - AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment - Business Upturn
- 23 days ago - Why are AstraZeneca Pharma shares down over 4% today? Explained - Business Upturn
- 24 days ago - AstraZeneca Pharma India Quarterly report: Q4 2026 - Filings
- 24 days ago - AstraZeneca Pharma India reports 33% revenue growth for FY 2025-26 - Business Upturn
- 4 weeks ago - AstraZeneca Pharma India gets CDSCO nod for expanded use of Calquence in Mantle Cell Lymphoma Treatment - Business Upturn
- 4 weeks ago - AstraZeneca designates key managerial personnel for materiality determination - Business Upturn